Reintroducing
About us / Press room
News about our community
Our actions match our words
February 16, 2018
ORTHO DERMATOLOGICS PRESENTS AN ANALYSIS OF SILIQ™ (BRODALUMAB) INJECTION PHASE 3 DATA ON DISEASE-RELATED ANXIETY AND DEPRESSION IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

Separate Phase 3 Analysis Highlights Long-Term Safety Profile Of SILIQ

RALEIGH, N.C., Feb. 16, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE: VRX and TSX: VRX), today announced results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the first time at the 76th Annual Meeting of the American Academy of Dermatology (AAD), Feb. 16-20, 2018, in San Diego.

February 14, 2018
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR JEMDEL™ PLAQUE PSORIASIS TREATMENT

LAVAL, Quebec, Feb. 14, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application for JEMDEL™1 (halobetasol propionate 0.01%) (IDP-122) lotion with a PDUFA action date of Oct. 5, 2018. If approved, JEMDEL will be the first highpotency topical steroid treatment for plaque psoriasis with dosing for as long as eight weeks. In the clinical trials, the most common adverse event was upper respiratory tract infection.

February 13, 2018
ORTHO DERMATOLOGICS SUPPORTS STUDENTS TREATED FOR DERMATOLOGIC CONDITIONS THROUGH ASPIRE HIGHER SCHOLARSHIPS

Submission Period for Applications Open through April 28, 2018

RALEIGH, N.C., Feb. 13, 2018 – Ortho Dermatologics today announced it will begin accepting applications for the 2018 Aspire Higher scholarship program for students who have been affected by dermatologic conditions. Through the program, nine students will receive a scholarship of $10,000.

“Pursuing higher education is an extraordinary milestone in people’s lives and at Ortho Dermatologics, we understand that the journey for those living with a dermatologic condition can come with additional personal challenges,” said Bill Humphries, executive vice president and group company chairman, Ortho Dermatologics. “For that reason, we are proud to continue the Aspire Higher scholarship program and honor outstanding students who have managed the difficulties of living with a skin condition while focusing on achieving their educational goals.”

 

January 22, 2018
ORTHO DERMATOLOGICS ANNOUNCES COMMERCIAL AVAILABILITY OF RETIN-A MICRO® (TRETINOIN) GEL MICROSPHERE 0.06% TOPICAL TREATMENT FOR ACNE VULGARIS

RALEIGH, N.C., Jan. 22, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE: VRX and TSX: VRX), today announced that RETIN-A MICRO® (tretinoin) gel microsphere 0.06% will be available commercially to health care professionals on January 22, 2018. The U.S. Food and Drug Administration (FDA) approved the Supplemental New Drug Application (sNDA) for RETIN-A MICRO® (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgaris on October 24, 2017.

January 12, 2018
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR IDP-121 ACNE TREATMENT IN LOTION FORM

LAVAL, Quebec, Jan. 12, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) , today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for IDP-121 (tretinoin 0.05%) lotion (ALTRENOTM1) with a PDUFA action date of Aug. 27, 2018. If approved, ALTRENO will be the first tretinoin product in lotion form rather than a gel or cream.

December 6, 2017
Scholarships Awarded to Students with Dermatologic Conditions

Scholarships were awarded to 9 recipients through the Aspire Higher Scholarship program. The winners of the program are applicants or current attendees of an accredited, nonprofit, 2- or 4-year college, university, or advanced (post-high school) vocational or technical school who have been treated for a dermatologic condition.

November 14, 2017
ORTHO DERMATOLOGICS ANNOUNCES ASPIRE HIGHER SCHOLARSHIP HONOREES

Scholarship Program Awards Students Across the Country Impacted by Dermatologic Conditions 

Raleigh, NC, November 14, 2017 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, today announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or four-year college, university, or advanced (post-high school) vocational or technical school who have been treated for a dermatologic condition.

November 2, 2017
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR IDP-118, NOVEL PLAQUE PSORIASIS TREATMENT

PDUFA Date Set for June 18, 2018

LAVAL, Quebec, Nov. 2, 2017 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018.

If approved, IDP-118 will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.

The most common adverse events were contact dermatitis (7.4%) and application site pain (2.6%).

October 12, 2017
ORTHO DERMATOLOGICS ANNOUNCES TWO-YEAR FINDINGS FROM PIVOTAL PHASE 3 STUDY OF SILIQ™ (BRODALUMAB) INJECTION DATA DEMONSTRATING LONG-TERM EFFICACY PROFILE

Data Sets Demonstrating Efficacy and Quality of Life Profile of SILIQ Presented at 2017 Fall Clinical Dermatology Conference

RALEIGH, N.C., Oct. 12, 2017 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced results from the Pivotal Phase 3 long-term extension study (AMAGINE-2), which demonstrated that SILIQ™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis. These findings are being presented for the first time today at the 2017 Fall Clinical Dermatology Conference in Las Vegas.

October 10, 2017
ORTHO DERMATOLOGICS TO PRESENT SILIQ™ (BRODALUMAB) INJECTION DATA FROM PIVOTOL PHASE III CLINICAL TRIAL AT FALL CLINICAL DERMATOLOGY CONFERENCE

RALEIGH, N.C., Oct. 10, 2017 – Ortho Dermatologics, one of the largest prescription dermatology businesses in the world, announced today that results from the SILIQ™ pivotal Phase 3 long-term extension study will be presented at the Fall Clinical Dermatology Conference in Las Vegas on October 12 – 15, 2017. In total, six new abstracts will be presented, including new data about the long-term efficacy of SILIQ, the efficacy of SILIQ in ustekinumab-naïve and -experienced patients with moderate-to-severe plaque psoriasis, as well as the impact of SILIQ treatment on health-related quality of life.

X
X
X